Encouragingly, inhibitors of human SCD have already been approved for clinical trials in obesity (study identifier; NCT02647970) and more recently in Parkinson’s disease (Yumanity); our data support their testing in AD patients as well. Here, SCD is linked to obesity due to melanocortin 4 receptor deficiency.